week 2 of semaglutide results by week: timeline from first dose to full results Semaglutide week 2 update! :

Notably, the glucose transporter-2 (GLUT2) has been implicated in glucose-stimulated GLP-1 secretion, as demonstrated by an impaired GLP-1 response to oral glucose in mice deficient for GLUT2, and this is accompanied by reduced glucose-stimulated insulin secretion and impaired glucose tolerance [272]

Now what

Why its interesting: The actives are familiar, but SkinCeuticals stands out by testing specifically on GLP-1 patients making the positioning fresher than the formula itself

HFpEF is the most common form of heart failure and a significant unmet need in cardiology with limited treatment options 22,23

The most frequently reported clinical outcomes included initial hospitalization or prolonged hospitalization (13.6%) and other serious medical events (12.3%)

Drug Manufacturers During the model pre-implementation period in early 2026, CMS negotiated with Novo Nordisk and Eli Lilly to come to agreement on the key parameters of the model, including details about pricing of the model drugs, cost sharing, rebate calculations, access policies (i.e., coverage criteria and prior authorization policies), the length of the agreement, data sharing arrangements, and agreement on lifestyle supports that will be offered